INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Reference |
|---|
| "Treatment of chronic hepatitis B is directed at interrupting the natural history and clinical outcomes of the disease." | ( Farrell, GC, 2000) |
| "Chronic hepatitis B is an international health concern that causes cirrhosis, hepatocellular carcinoma, liver failure, and death." | ( Wallace, AE; Weeks, WB, 2001) |
| "(1) Chronic hepatitis B is defined by the persistence of circulating HBs antigen for more than 6 months." | ( , 2001) |
| "Treatment of chronic hepatitis B is directed at interrupting the natural history by suppressing HBV replication before development of any significant irreversible liver cell damage." | ( Pramoolsinsup, C, 2002) |
| "Children with chronic hepatitis B are at risk of developing long-term complications such as cirrhosis and hepatocarcinoma." | ( Sokal, E, 2002) |
| "Chronic hepatitis B is a leading cause of death worldwide." | ( Anschuetz, G; Brown, NA; Davis, R; Fontana, RJ; Gardner, SD; Hann, HW; Perrillo, RP; Rakela, J; Vierling, JM; Wright, T, 2002) |
| "Treatment of chronic hepatitis B is aimed at sustained suppression of HBV replication and remission of liver disease." | ( Lok, AS; Wai, CT, 2002) |
| "Chronic hepatitis B is a serious long-term problem for children surviving malignancy." | ( Benesch, M; Deutsch, J; Dornbusch, HJ; Kerbl, R; Kessler, HH; Lackner, H; Moser, A; Schwinger, W; Sovinz, P; Urban, C, 2002) |
| "LAM+IFN therapy for chronic hepatitis B is tolerated and more effective than IFN monotherapy in inhibiting viral replication and getting ALT normalization." | ( Chen, YM; Deng, H; Xu, QH; Yao, JL; Zhao, ZX; Zhou, YP, 2003) |
| "Current therapy for chronic hepatitis B is suboptimal as a result of limited durable response rates, cumulative viral resistance, and/or poor tolerability." | ( Brown, NA; Chao, GC; Lai, CL; Lee, YM; Lim, SG; Lloyd, DM; Myers, MW; Yuen, MF; Zhou, XJ, 2004) |
| "Treatment of chronic hepatitis B is aimed at sustained suppression of HBV replication and remission of liver disease." | ( Bahar, A; Karademir, F, 2004) |
| "Some children with chronic hepatitis B are candidates for treatment." | ( Jonas, MM, 2006) |
| "Chronic hepatitis B is a common disease and approximately 20% of infected patients with compensated cirrhosis will decompensate over 5 years." | ( Haché, C; Villeneuve, JP, 2006) |
| "Chronic hepatitis B is an important public health problem worldwide." | ( Berak, H; Cybula, A; Horban, A; Stańczak, JJ; Wasilewski, M, 2006) |
| "Chronic hepatitis B is associated with complications of end-stage liver disease, including cirrhosis and hepatocellular carcinoma." | ( Ruiz-Sancho, A; Sheldon, J; Soriano, V, 2007) |
| "Chronic hepatitis B is a worldwide health problem." | ( Chan, HL; Lui, YY, 2008) |
| "Chronic hepatitis B is still a major public health problem, aggravated by the growing phenomenon of immigration from areas with a high prevalence of infection with this virus." | ( González-Diéguez, ML; Rodríguez, M, 2008) |
| "Chronic hepatitis B is a serious health problem worldwide with a substantial minority of patients experiencing premature death due to end-stage liver disease and/or hepatocellular carcinoma." | ( Keeffe, EB; Nguyen, MH, 2009) |
| "Chronic hepatitis B is a worldwide health problem." | ( Chan, HL; Lui, YY, 2009) |
| "Chronic hepatitis B is considered a major public health problem, and its treatment entails increasing health budget expenses with high-cost drugs covered by Unified National Health System." | ( Acurcio, Fde A; Almeida, AM; Guerra, AA; Silva, DI; Silva, GD, 2009) |
| "Chronic hepatitis B is the main risk factor for hepatocellular carcinoma (HCC) in Asia." | ( Kao, JH; Lim, SG; Mohammed, R; Yuen, MF, 2009) |
| "Chronic hepatitis B is a serious disease both worldwide and in the United States." | ( Duong, A; Mousa, SA, 2009) |
| "Chronic hepatitis B is an important cause of morbidity and mortality." | ( Asim, M; Das, BC; Gondal, R; Kar, P; Medhi, S; Pradeep Kumar, S, 2011) |
| "Treatment of chronic hepatitis B is still challenging." | ( Tornai, I, 2011) |
| "Flares in chronic hepatitis B are often detrimental but sometimes lead to sustained immune control and disease remission." | ( Hansen, BE; Janssen, HL; Perquin, M; Reijnders, JG; Zhang, NP, 2011) |
| "Chronic hepatitis B is characterized by an impaired immune response to hepatitis B virus (HBV)." | ( Bai, XF; Li, Y; Lian, JQ; Nan, XP; Peng, MJ; Su, WJ; Sun, RL; Wang, JP; Yu, HT; Zhang, Y, 2012) |
| "Childhood acquired chronic hepatitis B is associated with a significant lifetime risk of developing cirrhosis or hepatocellular carcinoma." | ( Al-Harthi, S; Al-Mughales, J; Bin-Talib, Y; Saadah, OI; Sindi, HH, 2012) |
| "Chronic hepatitis B is a common, progressive disease, particularly when viral replication is detected." | ( Buti, M; Casado, MA; Lozano, V; Oyagüez, I, 2013) |
| "Management of chronic hepatitis B is a global public health challenge." | ( Abraham, P; Eapen, CE; Ismail, AM; Kannangai, R; Ramachandran, J; Samuel, P, 2014) |
| "Chronic hepatitis B is generally a mild disease in children; however, response to therapy is partial and limited to specific subgroups, and available drugs have no proven advantage on long-term course of disease versus no treatment, and are hampered by numerous limitations." | ( Giagnorio, MG; Giannattasio, A; Iorio, R; Spagnuolo, MI; Tufano, M, 2014) |
| "Chronic hepatitis B is an important health problem worldwide." | ( Atmaca, S; Mese, S; Ozbek, E; Ozekinci, T, 2014) |
| "Chronic hepatitis B is a major cause of morbidity and mortality worldwide." | ( den Eynde, EV; Riveiro-Barciela, M, 2016) |
| "Chronic hepatitis B is a common, progressive disease, particularly when viral replication is detected." | ( Basile, M; Cicchetti, A; Coretti, S; Drago, C; Ruggeri, M, 2017) |
| "Chronic hepatitis B is a progressive disease that can develop into cirrhosis, liver cancer or even liver failure if it is not treated in time." | ( Wang, Y; Zhao, LF, 2017) |
| "Chronic hepatitis B is a problem in women of reproductive age." | ( Asci, Z; Demir, LS; Demir, NA; Kolgelier, S; Ozcimen, S; Sumer, S; Ural, O, 2016) |
| "Chronic hepatitis B is a severe liver disease caused by hepatitis B virus (HBV) infection." | ( Brezgin, S; Chulanov, V; Goptar, I; Kostyushev, D; Kostyusheva, A; Utkina, A; Zarifyan, D, 2019) |
| "Chronic hepatitis B is often complicated with different degrees of hepatic fibrosis, which affects the quality of life." | ( Cheng, M; Feng, X; Ma, L; Wang, B; Wang, L; Yang, Y, 2020) |
| "Chronic hepatitis B is an important public health concern." | ( Park, JY; Song, JE, 2021) |
| Excerpt | Reference |
|---|
| "Due to its low efficacy, 40% in the treatment of chronic hepatitis B and 10-20% in the treatment of chronic hepatitis C, and to its adverse events, in some cases severe, new antiviric molecules are being investigated." | ( Córdoba Cortijo, J; López Viedma, B; Olaso Peiró, V, 1998) |
| "Two patients were treated for chronic hepatitis B with lamivudine and subsequently underwent renal transplantation." | ( Han, DJ; Jung, YO; Lee, YS; Park, JS; Park, SK; Yang, WS, 1998) |
| "A consensus meeting on the treatment of chronic hepatitis B infection was conducted in Hong Kong, in August 1997." | ( Carman, WF; Lam, SK; Lau, GK; Locarnini, SA; Lu, ZM; Okuda, K; Williams, R, 1999) |
| "It has achieved a milestone in the treatment of chronic hepatitis B and is now commercially available in many countries." | ( Leung, N, 2000) |
| "Standard treatment of chronic hepatitis B virus infection includes the use of interferon-a and antiviral nucleoside analogues, alternatively." | ( Gerken, G, 2000) |
| "Immunomodulatory approaches to treatment of chronic hepatitis B are conceptually attractive, but newer agents used to date (thymalfasin, interleukin-12, therapeutic vaccines) have not demonstrated sufficient efficacy for widespread use." | ( Farrell, GC, 2000) |
| "Larger studies with lamivudine treatment in chronic hepatitis B were mainly performed in North America and Asia." | ( Berg, T; Kallinowski, B; Löhr, HF; Müller, R; Teuber, G; Zeuzem, S, 2001) |
| "Our study shows that lamivudine treatment in chronic hepatitis B can restore CTL reactivity, making CTL susceptible to exogenous stimulation." | ( Bertoletti, A; Boehme, R; Boni, C; Cavalli, A; Cavallo, C; Ferrari, C; Fiaccadori, F; Ogg, GS; Panebianco, R; Penna, A; Pilli, M; Urbani, S, 2001) |
| "In patients treated for chronic hepatitis B infection the cumulative incidence of viral resistance reaches over 50% after 3 years." | ( Fischer, KP; Gutfreund, KS; Tyrrell, DL, 2001) |
| "In the interferon (IFN) treatment of chronic hepatitis B, there is no accepted definition of virological response as measured by highly sensitive HBV DNA assays." | ( Hannoun, C; Horal, P; Krogsgaard, K; Lindh, M, 2001) |
| "For the treatment of chronic hepatitis B (CHB) two drugs have been licensed world-wide: interferon-alpha (IFN) and lamivudine." | ( de Man, RA; Janssen, HL; Niesters, HG; Schalm, SW; van Nunen, AB; Wolters, LM, 2001) |
| "Trials of thymosin treatment in chronic hepatitis B virus infection have been small and the results have been inconsistent." | ( Chan, HL; Sung, JJ; Tam, W; Tang, JL, 2001) |
| "placebo (or usual care) in the treatment of chronic hepatitis B virus infection were identified through MEDLINE, EMBASE and the Cochrane Register of Clinical Trials." | ( Chan, HL; Sung, JJ; Tam, W; Tang, JL, 2001) |
| "As to anti-viral treatment of chronic hepatitis B, the triplex superimposed treatment had better efficacy than lamivudine alone." | ( Du, KF; Liu, H; Lu, ZG; Wu, L; Xue, P, 2001) |
| "Lamivudine is registered for the treatment of chronic hepatitis B and can be used as a prophylactic prior to chemotherapy or to treat an exacerbation of the hepatitis." | ( de Man, RA; Doorduijn, JK; Janssen, HL; Niesters, HG; Schalm, SW; van der Eijk, AA, 2002) |
| "Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance." | ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002) |
| "Combination treatment of chronic hepatitis B with prednisone, IFN-alpha, and FAM seems to be a safe and effective treatment option for children surviving pediatric malignancy." | ( Benesch, M; Deutsch, J; Dornbusch, HJ; Kerbl, R; Kessler, HH; Lackner, H; Moser, A; Schwinger, W; Sovinz, P; Urban, C, 2002) |
| "We aimed to treat patients with chronic hepatitis B on long-term treatment with lamivudine who developed lamivudine-resistant hepatitis B virus (HBV) mutants along with clinical relapses." | ( Akuta, N; Arase, Y; Ikeda, K; Kobayashi, M; Kumada, H; Miyakawa, Y; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A, 2002) |
| "Oxymatrine is effective in treating chronic hepatitis B." | ( Chen, YX; Jiang, JH; Mao, BY, 2002) |
| "Lamivudine treatment in chronic hepatitis B leads to the reconstitution of virus-specific T cells in the circulation, but it is not clear whether this is the preferential result of T cell efflux from the liver or lymph nodes." | ( Behboudi, S; Bertoletti, A; Burroughs, AK; Dusheiko, GM; Gotto, J; Malacarne, F; Reignat, S; Webster, GJ; Williams, R, 2003) |
| "The results showed that after one year treatment of chronic hepatitis B with Lamivudine, the recovery rate of ALT was 90." | ( Chen, N; Cui, X; Li, X; Ru, H; Tang, Z; Wen, X; Xie, H; Zeng, W, 2002) |
| "Current therapies for the treatment of chronic hepatitis B virus (HBV) infection do not eliminate viral replication once therapy is stopped, resulting in a rapid rebound of viremia in a majority of patients." | ( Barcena Marugan, R; Cid Gomez, L; Lopez Serrano, P, 2003) |
| "In the treatment of chronic hepatitis B (CHB) with lamivudine, adequate duration of the therapy remains to be determined." | ( Choi, MH; Chung, YH; Jang, MK; Kim, JA; Lee, HC; Lee, YS; Park, NH; Ryu, SH; Shin, JW; Suh, DJ, 2003) |
| "It is indicated for the treatment of chronic hepatitis B in adults." | ( Dando, T; Plosker, G, 2003) |
| "During treatment of chronic hepatitis B with lamivudine, changes in the level of hepatitis B virus (HBV) DNA were investigated using a real-time polymerase chain reaction (PCR) method with a detection limit of 1." | ( Hino, T; Hisamochi, A; Ide, T; Koga, Y; Kumashiro, R; Kuwahara, R; Murashima, S; Ogata, K; Sata, M; Tanaka, E; Tanaka, K, 2003) |
| "Lamivudine is used for the treatment of chronic hepatitis B (CH-B), and exhibits excellent antiviral activity." | ( Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Matsuda, M; Saitoh, S; Satoh, J; Someya, T; Suzuki, F; Suzuki, Y; Takagi, K; Tsubota, A, 2004) |
| "HJD is effective for treating chronic hepatitis B, and its effect seems to relate with the improvement of the TCRVbeta7 expression of chronic hepatitis B patients, thus activating T cells and eliminating HBV." | ( Chen, ZX; Huang, BJ; Lao, SX; Zhang, SJ, 2004) |
| "Lamivudine was approved for the treatment of chronic hepatitis B in China in 1999; however the long-term result has not yet been reported in detail." | ( Cui, ZY; Wang, BE; Yao, GB; Yao, JL; Zeng, MD, 2004) |
| "Currently approved treatments for chronic hepatitis B are limited by low rates of sustained response, side effects, or drug resistance." | ( Lok, AS, 2004) |
| "Current therapies available for the treatment of chronic hepatitis B are limited in their ability to result in a cure." | ( Blum, MR; Bronowicki, JP; Conway, B; Lau, GK; Lee, HS; Marcellin, P; Mommeja-Marin, H; Mondou, E; Rousseau, F; Sacks, SL; Sereni, D; Snow, A; Sorbel, J; Trepo, C; Yoo, BC, 2004) |
| "Diagnosis and treatment of chronic hepatitis B serves prevention of liver cirrhosis and hepatocellular carcinoma as well as elimination of the sources of further infections." | ( Telegdy, L, 2004) |
| "The primary aim in the treatment of chronic hepatitis B is to induce sustained disease remission and prevent serious complications like liver failure and/or hepatocellular carcinoma." | ( Janssen, HL; Sprengers, D, 2005) |
| "A new nucleoside analog for treating chronic hepatitis B infection." | ( , 2005) |
| "Adefovir dipivoxil is indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (alanine [ALT] or aspartate [AST]) or histologically active disease." | ( Baker, DE, 2005) |
| "The efficacy of lamivudine re-treatment in chronic hepatitis B (CHB) patients who relapse after HBeAg seroconversion with lamivudine has not been investigated." | ( Bang, SJ; Jeong, ID; Joo, KR; Kim, DH; Park, JH; Park, NH; Shin, JW, 2005) |
| "Although lamivudine is effective for treatment of chronic hepatitis B (HBV) infection, its potential therapeutic impact on HBV-related membranous nephropathy (MN) in adults has not been characterized." | ( Chan, KW; Ho, YW; Kung, NN; Lai, FM; Lai, KN; Leung, JC; Lui, YH; Tang, CS; Tang, S, 2005) |
| "Adefovir dipivoxil is safe for the treatment of chronic hepatitis B in patients with varying degrees of renal dysfunction and lamivudine-resistant HBV and results in biochemical and virological efficacy similar to that reported in the general population." | ( Brosgart, C; Chaix, ML; Currie, G; Fontaine, H; Morales, E; Nalpas, B; Pol, S; Serpaggi, J; Vallet-Pichard, A; Varaut, A; Verkarre, V, 2005) |
| "Recent guidelines for the treatment of chronic hepatitis B based on the accumulated knowledge on the disesase pathogenesis and treatment outcome are presented." | ( Morović, M, 2005) |
| "HJT is effective in treating chronic hepatitis B." | ( Chen, ZX; Gu, YL; Guan, SH; Hu, HT; Lao, SX; Zhang, CY; Zhang, SJ, 2005) |
| "Current treatments for chronic hepatitis B virus (HBV) infection include the use of interferon-alpha and of nucleoside analogs lamivudine, adefovir and entecavir." | ( Ang, TH; Bai, J; Chen, Y; Kong, KH; Lam, Y; Li, Y; Lim, SG; Tan, TM, 2006) |
| "There are 3 drugs registered to treatment of chronic hepatitis B: interferon, lamivudine and adefovir." | ( Halota, W; Pawłowska, M, 2006) |
| "Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir, while entecavir is expected to be licensed in the short term." | ( Buster, EH; Janssen, HL, 2006) |
| "Sequential treatment of chronic hepatitis B with lamivudine and interferon-alpha monotherapies is as effective as lamivudine-alone treatment in Chinese patients." | ( Han, B; Jin, LJ; Shi, M; Wang, RS; Xu, YP; Yang, ZJ; Zhang, H; Zhang, Y; Zhu, YF, 2006) |
| "Lamivudine is widely used for the treatment of chronic hepatitis B infection because of it's remarkable antiviral efficacy and safety." | ( Baik, du S; Kim, BH; Kim, HJ; Kim, SB; Seo, PJ; Shin, JE; Song, IH; Yun, SY, 2006) |
| "Standard treatments for chronic hepatitis B (CHB) include interferon-alpha (IFN-alpha) and lamivudine (LAM), but these are associated with adverse effects and viral resistance, respectively." | ( Davidson, P; Jones, J; Price, A; Shepherd, J; Takeda, A, 2007) |
| "The results suggest that antioxidant treatment for chronic hepatitis B patients may help improve the effect of anti-virus therapy." | ( Fan, YC; Han, LY; Hou, YD; Li, XH; Wang, HM; Wang, K; Wang, LY, 2007) |
| "Six drugs have been approved for the treatment of chronic hepatitis B: interferon-alpha(2b), pegylated interferon-alpha(2a), lamivudine, adefovir, entecavir and telbivudine." | ( Ruiz-Sancho, A; Sheldon, J; Soriano, V, 2007) |
| "Peginterferon alpha-2a (40 kDa), a new treatment for chronic hepatitis B, produces seroconversion within 48 weeks in approximately 32% of HBeAg-positive patients." | ( Aledort, JE; Dusheiko, GM; Jacobs, M; Lewis, G; Patel, KK; Sullivan, SD; Veenstra, DL, 2007) |
| "We analyzed 49 LAM-treated chronic hepatitis B patients infected with hepatitis B virus (HBV) genotype C." | ( Fukai, K; Imazeki, F; Kurihara, T; Mikata, R; Yokosuka, O; Zhang, KY, 2007) |
| "Lamivudine is used for the treatment of chronic hepatitis B patients." | ( Aghakhani, A; Banifazl, M; Gachkar, L; Keyvani, H; Ramezani, A; Roshan, MR; Velayati, AA, 2008) |
| "Long-term effects of lamivudine treatment on chronic hepatitis B patients without advanced disease remain unknown." | ( Chow, DH; Fung, J; Lai, CL; Ngai, VW; Seto, WK; Tsui, K; Wong, BC; Wong, DK; Yuen, JC; Yuen, MF, 2007) |
| "Adefovir dipivoxil (ADV) is a licensed treatment for chronic hepatitis B in adults." | ( Dhawan, A; Frederick, D; Kelly, D; Mizerski, J; Sokal, EM; Wirth, S, 2008) |
| "The ultimate goal of treatment for chronic hepatitis B (CHB) is to prevent hepatocellular carcinoma (HCC)." | ( Hann, HW, 2008) |
| "Entecavir (ETV) was developed for the treatment of chronic hepatitis B virus (HBV) infection and is globally approved for that indication." | ( Colonno, R; Dicker, I; Fan, L; Gali, V; Higley, H; Krystal, M; Lin, PF; Nowicka-Sans, B; Parkin, N; Tenney, D; Terry, B; Wang, C; Zhang, S, 2008) |
| "To review the current treatment of chronic hepatitis B, with a focus on diagnosis and management of resistance and active management of suboptimal responses." | ( Ayoub, WS; Keeffe, EB, 2008) |
| "Among the six drugs licensed for the treatment of chronic hepatitis B in the US, the preferred agents in 2008 will include entecavir, peginterferon alfa-2a, possibly telbivudine, and tenofovir following licensure." | ( Ayoub, WS; Keeffe, EB, 2008) |
| "The main goal for treatment of chronic hepatitis B is to prevent complications such as liver cirrhosis or hepatocellular carcinoma." | ( Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J, 2008) |
| "To study the efficacy of lamivudine treatment in chronic hepatitis B patients affected by structures of HBV P-genes." | ( Jiang, JJ; Wang, YP; Yan, YS, 2008) |
| "Of currently available drugs for the treatment of chronic hepatitis B, PEG-IFN seems to result in the highest rate of off-treatment sustained response after a 1-year course of therapy." | ( Buster, EH; Janssen, HL; Schalm, SW, 2008) |
| "To explore the strategy for the treatment of chronic hepatitis B with YMDD mutation." | ( Dai, YX; Ding, H; Hu, TH; Huang, LH; Jiang, XH; Jiang, YM; Qiu, YW; Zhou, M, 2009) |
| "Diagnosis and treatment of chronic hepatitis B (CHB) have improved in recent years with introduction of new oral antiviral drugs." | ( Buti, M; Córdoba, J; Esteban, R; García-Martínez, R; Les, I; Quintana, M, 2009) |
| "The initial treatment for chronic hepatitis B was interferon." | ( Kao, JH; Lim, SG; Mohammed, R; Yuen, MF, 2009) |
| "In adefovir (ADV) treated chronic hepatitis B patients carrying rtA181T/rtA181V mutations, overlap with surface gene mutations such as sW172stop/sL173F has been reported." | ( Bak, YT; Byun, KS; Joo, MK; Jung, YK; Kim, JH; Kim, JS; Park, JJ; Yeon, JE; Yim, HJ, 2010) |
| "Since its approval for the treatment of chronic hepatitis B in 1998, lamivudine (LAM) has been used extensively throughout the world, because of its relatively low costs and favourable tolerability." | ( Marcellin, P; Piratvisuth, T; Sung, J, 2010) |
| "Clevudine has been approved for the treatment of chronic hepatitis B (CHB) in South Korea." | ( Hwang, JH; Jang, JH; Jeong, SH; Kim, HS; Kim, JW; Kim, N; Lee, DH; Lee, SH; Myung, HJ; Park, YS, 2011) |
| "Such is the case for antivirals used to treat chronic hepatitis B." | ( Tenney, DJ, 2010) |
| "Current agents used in the treatment of chronic hepatitis B (CHB) can be classified into interferons-α (IFN-α: standard or pegylated) and nucleos(t)ide analogues (NUCs)." | ( Papatheodoridis, GV, 2011) |
| "Major progress in the treatment of chronic hepatitis B (CHB) has been made during the last decade with the development of antivirals that inhibit viral polymerase activity." | ( Zoulim, F, 2011) |
| "Adefovir dipivoxil is commonly used for treatment of chronic hepatitis B." | ( Dong, GF; Li, L; Xie, YS; Zhang, X, 2011) |
| "Entecavir is an effective treatment for chronic hepatitis B." | ( Bonet, L; Buti, M; Diago, M; García-Samaniego, J; Morillas, RM; Palau, A; Pérez, J; Prieto, M; Rodríguez, M; Solà, R; Testillano, M, 2012) |
| "The effectiveness of antiviral treatments of chronic hepatitis B has been poorly studied in Brazil." | ( Fernandes, CA; Gomes, Sde A; Mello, FC, 2012) |
| "ETV is effective in treating chronic hepatitis B in RTRs." | ( Chang, KC; Chen, TC; Chen, YT; Chien, YS; Chiu, KW; Hu, TH; Lin, MT; Tsai, MC, 2012) |
| "There are five approved drugs for the treatment of chronic hepatitis B(lamivudine, adefovir dipivoxil [ADV], entecavir [ETV], as well as pegylated and standard interferon) in Japan." | ( Suzuki, F, 2012) |
| "In the first year of treatment for chronic hepatitis B, virologic response and tolerability did not differ significantly between tenofovir and entecavir." | ( Akin, MS; Doğan, ÜB; Gümürdülü, Y; Kara, B; Soylu, A, 2012) |
| "New insights into the treatment of chronic hepatitis B with relevance for clinical practice have been adopted in these concise, revised guidelines." | ( Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM, 2012) |
| "Currently available antiviral treatment for chronic hepatitis B virus infection can be divided into two classes of therapeutic agents: nucleos(t)ide analogues (NAs) and interferon (IFN)." | ( Enomoto, M; Kawada, N; Nishiguchi, S; Tamori, A, 2013) |
| "The ideal approach to treat chronic hepatitis B remains controversial." | ( Hagiwara, S; Inoue, T; Inuzuka, T; Kudo, M; Matsumoto, A; Matsuo, H; Nishida, N; Osaki, Y; Sakurai, T; Tanaka, E; Ueshima, K; Yada, N, 2013) |
| "Should treatment of chronic hepatitis B virus infection be necessary during pregnancy, tenofovir, listed by the FDA as pregnancy category B drug, is to be preferred." | ( Horváth, G, 2013) |
| "One major challenge in the treatment of chronic hepatitis B is to maintain long-term viral suppression without promoting the selection of drug-resistant mutations." | ( Borroto-Esoda, K; Corsa, A; Flaherty, J; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD; Snow-Lampart, A, 2014) |
| "The efficacy of entecavir (ETV) treatment in chronic hepatitis B (CHB) patients who were exposed to lamivudine (LAM) but had no detectable LAM resistance (LAM-R) is not well evaluated." | ( Cho, Y; Cho, YY; Choi, WM; Kim, YJ; Lee, DH; Lee, HS; Lee, JH; Lee, M; Lee, YB; Yoo, JJ; Yoon, JH; Yu, SJ, 2014) |
| "Entecavir (ETV) is effective in the treatment of chronic hepatitis B virus (HBV) infections, even in patients with underlying cirrhosis." | ( Byun, KS; Hyun, JJ; Kang, S; Kim, HR; Kim, JH; Kim, SY; Koo, JS; Lee, SW; Seo, YS; Suh, SJ; Um, SH; Yeon, JE; Yim, HJ, 2015) |
| "Five nucleos(t)ide analogs are used to treat chronic hepatitis B." | ( Shan, C; Wu, P; Yin, GQ, 2014) |
| "Current agents for the treatment of chronic hepatitis B (CHB) can be classified into interferon-α (standard or pegylated) (IFN) and nucleos(t)ide analogues (NAs)." | ( Papatheodoridis, GV; Vlachogiannakos, J, 2015) |
| "Currently available antiviral treatment for chronic hepatitis B can be divided into two classes of therapeutic agents: pegylated interferon alpha (PEG-IFN) and nucleos(t)ide analogues (NAs)." | ( Dandri, M; Petersen, J, 2015) |
| "Of the 199 treatment-naive chronic hepatitis B patients, 141 (70." | ( Aktuğ Demir, N; Kölgelier, S; Özçimen, S; Sümer, Ş, 2014) |
| "The goal of treatment for chronic hepatitis B (CHB) is now to improve quality of life and to prevent the poor outcomes of the disease rather than to eliminate the virus from the body." | ( Abdurakhmanov, DT; Otrashevskaya, AV, 2014) |
| "Entecavir (ETV) is approved for the treatment of chronic hepatitis B virus (HBV) infections, but the virus can acquire resistance to the drug." | ( Hayashi, S; Iio, E; Isogawa, M; Karino, Y; Matsui, T; Murakami, S; Omagari, K; Tanaka, Y; Watanabe, T, 2015) |
| "Long-term usage of lamivudine in the treatment of chronic hepatitis B virus (HBV) infection induces the emergence of drug resistance." | ( Li, P; Lil, K; Liu, B; Pan, Y; Pu, W; Sun, A; Zhang, J; Zhang, R; Zhou, C, 2015) |
| "Lamivudine is an antiviral used for the treatment of chronic hepatitis B." | ( Calica Utku, A; Karabay, O, 2016) |
| "The goal of oral antiviral treatment for chronic hepatitis B (CHB) is to achieve and maintain undetectable HBV DNA levels." | ( Berg, T; Caruntu, FA; Elkhashab, M; Fabri, M; Flaherty, JF; Fung, S; Gane, E; Gurel, S; Hann, HW; Horban, A; Husa, P; Jablkowski, MS; Kim, K; Kitrinos, KM; Kwan, P; Massetto, B; McHutchison, JG; Pelemis, M; Sporea, I; Subramanian, GM; Yee, LJ; Yurdaydin, C, 2017) |
| "A major hurdle in the long-term treatment of chronic hepatitis B (CHB) patients is to maintain viral suppression in the absence of drug resistance." | ( Buti, M; Cathcart, AL; Corsa, AC; Flaherty, JF; Gane, EJ; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD, 2017) |
| "One thousand and nine treatment-naïve chronic hepatitis B (CHB) patients were evaluated for cumulative rates of virologic response, biochemical response, and entecavir mutations." | ( Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2017) |
| "A retrospective cohort of 875 treatment-naive chronic hepatitis B virus (HBV) monoinfected patients (mean age 47." | ( Choi, MS; Gwak, GY; Kang, W; Kim, JH; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH, 2017) |
| "Current treatments for chronic hepatitis B (CHB) include pegylated interferon alpha (PEG-IFN-α) which is an immune modulator, and nucleos(t)ide analogs (NAs) which directly inhibit HBV DNA polymerase." | ( Guo, H; Jiao, J; Liu, Z; Qi, W; Wang, J; Wang, X; Xu, Y; Yu, F; Zhao, P; Zhou, C, 2017) |
| "New therapies to treat chronic hepatitis B (CHB) are urgently needed." | ( Barry, V; Daffis, S; Delaney, WE; Fletcher, SP; French, DM; Huntzicker, E; Lanford, RE; Li, L; Mikaelian, I; Niu, C, 2018) |
| "Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression." | ( Buti, M; Esteban, R; Riveiro-Barciela, M, 2018) |
| "This retrospective study included treatment-naïve chronic hepatitis B patients who received at least 2 years of consecutive entecavir treatment." | ( Chang, TT; Chen, CY; Cheng, PN; Chiu, HC; Chiu, YC; Lin, TC; Liu, WC; Wu, IC, 2018) |
| "She had initially been treated for chronic hepatitis B infection with lamivudine and tenofovir, complicated by portal hypertension and variceal bleeding that thrice required banding." | ( Lelei-Mailu, FJ; Mariara, CM, 2018) |
| "Entecavir (ETV) is commonly used to treat chronic hepatitis B (CHB) in China." | ( Li, XX; Liu, XZ; Ren, GJ; Sun, D; Xu, HC; Ye, H; Zhuang, YL, 2018) |
| "It is unclear whether drugs used to treat chronic hepatitis B virus (HBV) infection cause significant renal impairment." | ( Chang, ET; Cheung, R; Chung, M; Henry, L; Hoang, J; Jeong, D; Le, AK; Lee, MH; Nguyen, MH; Trinh, S; Wang, U, 2019) |
| "The use of lamivudine for the treatment of chronic hepatitis B (CHB) is limited by high rates of lamivudine resistance." | ( Berg, T; Brodzinski, A; Fülöp, B; Jung, MC; Koukoulioti, E; Mihm, U; Sarrazin, C; Schlosser, B; Schott, E; van Bömmel, F, 2019) |
| "One strategy to treat chronic hepatitis B virus (HBV) infection could be to increase the functions of virus-specific T cells." | ( Acerbi, G; Ahn, SH; Alfieri, A; Andreone, P; Barili, V; Boni, C; Brillo, F; Brunetto, MR; Cavallone, D; Coco, B; Cursaro, C; Ferrari, C; Fisicaro, P; Fung, S; Gaggar, A; Janssen, HLA; Joshi, A; Laccabue, D; Lau, AH; Ma, X; Mangia, A; Margotti, M; Massetto, B; Pedrazzi, G; Piazzolla, V; Rodell, TC; Rossi, M; Santoro, R; Subramanian, GM; Trinh, H; Vecchi, A; Woo, J; Yoon, SK; Yoshida, EM; Zhao, Y, 2019) |
| "Antiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-Saharan Africa; hence, little is known about the prognosis after initiating treatment in African CHB patients." | ( Aberra, H; Berhe, N; Desalegn, H; Gundersen, SG; Johannessen, A; Medhin, G; Mekasha, B, 2019) |
| "The aim of the treatment in chronic hepatitis B is to prevent progression to cirrhosis and liver cancer." | ( Aydın, N; Kırdar, S; Sayan, M; Yaşa, MH, 2019) |
| "We enrolled treatment-naïve chronic hepatitis B (CHB) and HBV-related liver cirrhosis (LC) patients treated with ETV for 24 months." | ( Cheng, LS; Jiang, W; Li, J; Liu, Y; She, WM; Shen, Y; Wang, SQ; Wu, SD, 2021) |
| "He had a history of untreated chronic hepatitis B virus infection for >29 years and no other underlying diseases." | ( Li, Q; Zhu, H, 2021) |
| "Current clinical guidelines recommend treating chronic hepatitis B virus (HBV) infection in a minority of cases, but there are relatively scarce data on evolution or progression of liver inflammation and fibrosis in cases of chronic HBV (CHB) that do not meet treatment criteria." | ( Barnes, E; Campbell, C; Collier, J; Cripps, S; Davies, J; Freeman, O; Jeffery, K; Matthews, PC; McNaughton, AL; Mokaya, J; Noble, T; Salih, H; Smith, DA; Várnai, KA; Wang, T; Woods, K, 2021) |
| "The treatment evidence for entecavir-treated chronic hepatitis B (CHB) patients without maintaining of virologic response (MVR, defined as persistent HBV DNA <20 IU/mL during therapy) remains uncertain." | ( Chen, Y; Cheng, K; Duan, X; Duan, Z; Liao, W; Lu, Y; Wang, L; Wang, X; Wang, Y; Xu, M, 2021) |
| "Tenofovir is wildly used to treat chronic hepatitis B (CHB) infection due to good potency and high genetic barrier to drug resistance." | ( Cen, S; Gu, J; Liu, T; Sun, Q; Zhang, Q, 2022) |
| "In sub-Saharan Africa, less than 1% of treatment-eligible chronic hepatitis B (CHB) patients receive antiviral therapy." | ( Aberra, H; Berhe, N; Desalegn, H; Grude, S; Gundersen, SG; Hommersand, K; Johannessen, A; Mamo, E; Orlien, SMS, 2023) |